Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Orphan drug designation for BAY-43-9006 for renal cell carcinoma

Nov. 2, 2004

Novel hypoxia-targeting agents for tumor therapy

Nov. 2, 2004

Novel CDK2/CDK5 inhibitors claimed by IRM researchers

Nov. 2, 2004

Novel Chk1 inhibitors and their use covered by AstraZeneca patent

Nov. 2, 2004

New tubulin polymerization inhibitors prepared and tested at Aventis

Nov. 2, 2004

Clearazide set to enter phase II/III studies in 2005

Oct. 29, 2004

Cloretazine receives orphan drug status

Oct. 29, 2004

New fungal derivative with antitumor and antiproliferative properties

Oct. 29, 2004

New indication for Sandostatin injection approved in Japan

Oct. 29, 2004

Promising phase II results reported for BAY-43-9006 in advanced kidney cancer

Oct. 28, 2004

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...